Safingol toxicology after oral administration to TRAMP mice: Demonstration of safingol uptake and metabolism by N-acylation and N-methylation

Drug and Chemical Toxicology

Volumn 30, Issue 3, 2007, Pages 197-216

  Morales, Pablo R ^a   Dillehay, Dirck L ^a,b   Moody, Steven J ^a   Pallas, David C ^a   Pruett, Sarah ^b   Allgood, Jeremy C ^c   Symolon, Holly ^c   Merrill Jr , Alfred H ^c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Cancer; Hepatotoxicity; Mass spectrometry; Safingol; Safingol metabolites; Sphingolipids; TRAMP mice

Indexed keywords

ALANINE AMINOTRANSFERASE; CERAMIDE; DRUG METABOLITE; NITROGEN; SAFINGOL; UREA;

ACYLATION; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPHAGY; CELL LINE; CELL VACUOLE; COMPARATIVE STUDY; CYTOTOXICITY; DIET; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG TISSUE LEVEL; DRUG UPTAKE; ELECTROSPRAY MASS SPECTROMETRY; LIQUID CHROMATOGRAPHY; LIVER; LIVER HISTOLOGY; LIVER TOXICITY; MALE; METHYLATION; MOUSE; NEPHROTOXICITY; NONHUMAN; PROSTATE; PROSTATE ADENOCARCINOMA; PROSTATIC INTRAEPITHELIAL NEOPLASIA; SPECIES; TRANSGENIC MOUSE; UREA NITROGEN BLOOD LEVEL;

ACYLATION; ADENOCARCINOMA; ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; BALB 3T3 CELLS; BIOTRANSFORMATION; BODY WEIGHT; CELL LINE, TUMOR; CELL SURVIVAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMATOCRIT; HUMANS; KIDNEY DISEASES; LIVER; LIVER DISEASES; MALE; METHYLATION; MICE; MICE, TRANSGENIC; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SPHINGOSINE; TISSUE DISTRIBUTION;

MUS;

EID: 34347401415     PISSN: 01480545     EISSN: 15256014     Source Type: Journal    
DOI: 10.1080/01480540701375018     Document Type: Article

References (40)

1. Buehrer, B. M., Bell, R. M. (1992). Inhibition of sphingosine kinase in vitro and in platelets. Implications for signal transduction pathways. J. Biol. Chem. 267:3154-3159.
2. Carfagna, M. A., Young, K. M., Susick, R. L. (1996). Sex differences in rat hepatic cytolethality of the protein Kinase C inhibitor Safingol: role of biotransformation. Toxicol. Appl. Pharmacol. 137(2):173-81.
3. Cuvillier, O. (2002). Sphingosine in apoptosis signaling. Biochim. Biophys. Acta. 1585:153-162.
4. Dillehay, D. L., Webb, S. K., Schmelz, E.-M., Merrill, A. H., Jr (1994). Dietary sphingomyelin inhibits 1,2-dimethylhydrazine-induced colon cancer in CF1 mice. J. Nutr. 124:615-620.
5. Foster, B. A., Gingrich, J. R., Kwon, E. D., Madias, C., Greenberg, N. M. (1997). Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res. 57:3325-3330.
6. Greenberg, N. M., DeMayo, F. J., Sheppard, P. C., Barrios, R., Lebovitz, R., Finegold, M., Angelopoulou, R., Dodd, J. G., Duckworth, M. L., Rosen, J. M., et al. (1994). The rat probasin gene promoter directs hormonally and developmentally regulated expression of a heterologous gene specifically to the prostate in transgenic mice. Mol. Endocrinol. 8:230-239.
7. Hannun, Y. A., Loomis, C. R., Merrill, A. H., Jr., Bell, R. M. (1986). Sphingosine inhibition of protein kinase C activity and of phorbol dibutyrate binding in vitro and in human platelets. J. Biol. Chem. 261:12604-12609.
8. Humpf, H. U., Schmelz, E. M., Meredith, F. I., Vesper, H., Vales, T. R., Wang, E., Menaldino, D. S., Liotta, D. C., Merrill, A. H., Jr. (1998). Acylation of naturally occurring and synthetic 1-deoxysphinganines by ceramide synthase. Formation of N-palmitoyl-aminopentol produces a toxic metabolite of hydrolyzed fumonisin, AP1, and a new category of ceramide synthase inhibitor. J. Biol. Chem. 273:19060-19064.
9. Igarashi, Y., Hakomori, S. (1989). Enzymatic synthesis of N,N-dimethyl-sphingosine: demonstration of the sphingosine: N-methyltransferase in mouse brain. Biochem. Biophys. Res. Commun. 164:1411-1416.
10. Inamine, M., Suzui, M., Morioka, T., Kinjo, T., Kaneshiro, T., Sugishita, T., Okada, T., Yoshimi, N. (2005). Inhibitory effect of dietary monoglucosylceramide 1-O-beta-glucosyl-N-2′-hydroxyarachidoyl-4,8- sphingadienine on two different categories of colon preneoplastic lesions induced by 1,2-dimethylhydrazine in F344 rats. Cancer Sci. 96:876-881.
11. Jarvis, W. D., Fornari, F. A., Jr., Tombes, R. M., Erukulla, R. K., Bittman, R., Schwartz, G. K., Dent, P., Grant, S. (1998). Evidence for involvement of mitogen-activated protein kinase, rather than stress-activated protein kinase, in potentiation of 1-beta-D-arabinofuranosylcytosine-induced apoptosis by interruption of protein kinase C signaling. Mol. Pharmacol. 54:844-856.
12. Kedderis, L., Bozigian, H., Kleeman, J., Hall, R., Palmer, Thomas E., Harrison, Steadman, D., Susick, R. (1995). Toxicity of the protein kinase C inhibitor safingol administered alone and in combination with chemotherapeutic agents. Fund. Appl. Toxicol. 25:201-217.
13. Komatsu, M., Waguri, S., Ueno, T., Iwata, J., Murata, S., Tanida, I., Ezaki, J., Mizushima, N., Ohsumi, Y., Uchiyama, Y., et al. (2005) Impairment of starvation-induced and constitutive autophagy in Atg7-deficient mice. J. Cell Biol. 3:425-434.
14. Lemonnier, L. A., Dillehay, D. L., Vespremi, M. J., Abrams, J., Brody, E., Schmelz, E. M. (2003). Sphingomyelin in the suppression of colon tumors: prevention versus intervention. Arch. Biochem. Biophys. 419:129-138.
15. Maurer, B. J., Melton, L., Billups, C., Cabot, M. C., Reynolds, C. P. (2000). Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl)retinamide and modulators of ceramide metabolism. J. Natl. Cancer Inst. 92:1897-1909.
16. Menaldino, D. S., Bushnev, A., Sun, A., Liotta, D. C., Symolon, H., Desai, K., Dillehay, D. L., Peng, Q., Wang, E., Allegood, J., et al. (2003). Sphingoid bases and de novo ceramide synthesis: enzymes involved, pharmacology and mechanisms of action. Pharmacol. Res. 47:373-3781.
17. Merrill, A. H., Jr., Sullards, M. C., Allegood, J. C., Kelly, S., Wang, E. (2005). Sphingolipidomics: high-throughput, structure-specific and quantitative analysis of sphingolipids by liquid chromatography tandem mass spectrometry. Methods 36:207-224.
18. Milstien, S., Spiegel, S. (2006). Targeting sphingosine-1-phosphate: a novel avenue for cancer therapeutics. Cancer Cell 9:148-150.
19. Nardacci, R., Sartori, C., Stefanini, S. (2000). Selective autophagy of clofibrate-induced rat liver peroxisomes. Cytochemistry and immunocytochemistry on tissue specimens and on fractions obtained by Nycodenz density gradient centrifugation. Cell. Mol. Biol. (Noisy-le-grand) 7:1277-1290.
20. National Research Council Guidelines. (1996). Publication No. 88-123 (rev). Bethesda, MD. NIH, 1985.
21. National Toxicology Program. (2001). Toxicology and carcinogenesis studies of fumonisin B1 (CAS no. 116355-83-0) in F344/N rats and B6C3F1 mice (feed studies). Natl. Toxicol. Program Tech. Rep. Ser. 2001 Dec. NTP Technical Report 496:1-352.
22. Ogretmen, B., Hannun, Y. A. (2004). Biologically active sphingolipids in cancer pathogenesis and treatment. Nat. Rev. Cancer 4:604-616.
23. Riley, R. T., Hinton, D. M., Chamberlain, W. J., Bacon, C. W., Wang, E., Merrill, A. H., Jr, Voss, K. A. (1994). Dietary fumonisin B1 induces disruption of sphingolipid metabolism in Sprague-Dawley rats: a new mechanism of nephrotoxicity. J. Nutr. 124:594-603.
24. Riley, R. T., Voss, K. A. (2006). Differential sensitivity of rat kidney and liver to fumonisin toxicity: organ specific differences in toxin accumulation and sphingoid base metabolism. Toxicol. Sci. (in press).
25. Sachs, C. W., Safa, A. R., Harrison, S. D., Fine, R. L. (1995). Partial inhibition of multidrug resistance by safingol is independent of modulation of P-glycoprotein substrate activities and correlated with inhibition of protein kinase C. J. Biol. Chem. 270:26639-26648.
26. Salas, M., Tuchweber, B., Kourounakis, P. (1980). Liver ultrastructure during acute stress. Pathol. Res. Pract. 167:217-233.
27. Schmelz, E. M. (2004). Sphingolipids in the chemoprevention of colon cancer. Front. Biosci. 9:2632-2629.
28. Schmelz, E. M., Crall, K. L., LaRocque, R., Dillehay, D. L., Merrill, A. H. Jr. (1994). Uptake and metabolism of sphingolipids in isolated intestinal loop of mice. J. Nutr. 124:702-712.
29. Schmelz, E. M., Dillehay, D., Webb, S., Reiter, A., Adams, J., Merrill, A. H., Jr. (1996). Sphingomyelin consumption suppresses aberrant colonic crypt foci and increases the proportion of adenomas versus adenocarcinomas in CF1 mice treated with 1,2-dimethylhydrazine: implications for dietary sphingolipids and colon carcinogenesis. Cancer Res. 56:4936-4941.
30. Schmelz, E. M., Roberts, P. C., Kustin, E. M., Lemmonnier, L. A., Sullards, M. C., Dillehay, D. L., Merrill, A. H., Jr. (2001). Modulation of intracellular β-catenin localization and intestinal tumorigenesis in vivo and in vitro by sphingolipids. Cancer Res. 61:6723-6729.
31. Schmelz, E. M., Sullards, M. C., Dillehay, D. L., Merrill, A. H., Jr. (2000). Inhibition of colonic cell proliferation and aberrant crypt foci formation by dietary glycosphingolipids in 1,2-dimethylhydrazine-treated CF1 mice. J. Nutr. 130:522-527.
32. Schwartz, G. K., Haimovitz-Friedman, A., Dhupar, S. K., Ehleiter, D., Maslak, P., Lai, L., Loganzo, F., Jr., Kelsen, D. P., Fuks, Z., Albino, A. P. (1995). Potentiation of apoptosis by treatment with the protein kinase C-specific inhibitor safingol in mitomycin C-treated gastric cancer cells. J. Natl. Cancer Inst. 87:1394-1399.
33. Schwartz, G. K., Ward, D., Saltz, L., Casper, E. S., Spiess, T., Mullen, E., Woodworth, J., Venuti, R., Zervos, P., Storniolo, A. M., Kelsen, D. P. (1997). A pilot clinical/pharmacological study of the protein kinase C-specific inhibitor safingol alone and in combination with doxorubicin. Clin. Cancer Res. 3:537-543.
34. Silins, I., Nordstrand, M., Hogberg, J., Stenius, U. (2003). Sphingolipids suppress preneoplastic rat hepatocytes in vitro and in vivo. Carcinogenesis 24:1077-1083.
35. Sosnowski, J., Stetter-Neel, C., Cole, D., Durham, J. P., Mawhinney, M. G. (1997). Protein kinase C mediated anti-proliferative glucocorticoid- sphinganine synergism in cultured Pollard III prostate tumor cells. J. Urol. 158:269-274.
36. Sullards, M. C., Lynch, D. V., Merrill, A. H., Jr., Adams, J. (2000) Structure determination of soybean and wheat glucosylceramides by tandem mass spectrometry. J Mass Spectrom. 35:347-353.
37. Suzuki, E., Handa, K., Toledo, M. S., Hakomori, S. (2004). Sphingosine-dependent apoptosis: a unified concept based on multiple mechanisms operating in concert. Proc. Natl. Acad. Sci. U. S. A. 101:14788-14793.
38. Symolon, H., Schmelz, E. M., Dillehay, D. L., Merrill, A. H., Jr. (2004). Dietary soy sphingolipids suppress tumorigenesis and gene expression in mouse models of colon cancer. J. Nutr. 134:1157-1161.
39. Vesper, H., Schmelz, E. M., Nikolova-Karakashian, M. N., Dillehay, D. L., Lynch, D. V., and Merrill, A. H., Jr. (1999). Sphingolipids in food and the emerging importance of sphingolipids to nutrition. J. Nutr. Sci. 129:1239-1250.
40. Zheng, W., Kollmeyer, J., Symolon, H., Momin, A., Munter, E., Wang, E., Kelly, S., Allegood, J. C., Liu, Y., Peng, Q., et al. (2006). Ceramides and other bioactive sphingolipid backbones in health and disease: lipidomic analysis, metabolism and roles in membrane structure, dynamics, signaling and autophagy. Biochim. Biophys. Acta. 1758:1864-1884.